I totally agree. But I think the read outs on the PTX 100 Basket study trial and the PTX 200 AML trials will be a few years ahead of the CarT for Breast and Ovarian treatments.
Patients on the trial for PTX 100 are already showing extended survival than predicted. And this is from low dose early in the phase 1. PTX 200 has already reported 3 CRs with the phase 2b AML trial. Its safety has improved after trial redesign. And it has FDA ODD already.
Either of these two are company makers by themselves. Add to that the OmniCar potential and PTX shows huge potential for its low market cap.
Keep in mind RACs market cap when at 5c was much lower than where PTX is now. So although I am looking forward to a PTX rerate, I think we have to be realistic in expectations.
- Forums
- ASX - By Stock
- PTX
- updated chart
updated chart, page-49
-
- There are more pages in this discussion • 3,230 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
Add PTX (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 4.0¢ | $2.346K | 57.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 262409 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 128000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 262409 | 0.040 |
5 | 383358 | 0.039 |
3 | 750222 | 0.038 |
10 | 942682 | 0.037 |
6 | 594444 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 128000 | 2 |
0.043 | 172342 | 1 |
0.044 | 385807 | 4 |
0.045 | 423919 | 4 |
0.046 | 98002 | 1 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |